Provider Briefing: Cefprozil Availability in 2026

If your patients have been reporting difficulty filling Cefprozil prescriptions, the data confirms what you're hearing. Cefprozil — a second-generation cephalosporin widely prescribed in primary care, pediatrics, and urgent care — has experienced supply disruptions that continue into 2026.

This guide summarizes the current availability picture, clinical implications for your prescribing decisions, cost and access considerations, and tools to improve patient outcomes during the shortage.

Shortage Timeline

The Cefprozil supply situation has evolved over several years:

• 2022–2023: A surge in respiratory infections (RSV, influenza, COVID-19) drove unprecedented demand for oral antibiotics. Amoxicillin shortages cascaded into increased prescribing of cephalosporins including Cefprozil.
• 2023–2024: The FDA listed Cefprozil oral suspension as intermittently unavailable. Manufacturing challenges at multiple generic facilities contributed to supply gaps.
• 2024–2025: Partial recovery in tablet supply. Oral suspension availability remained inconsistent due to limited production capacity for pediatric formulations across the cephalosporin class.
• Early 2026: Tablets are generally available with regional exceptions. Oral suspension continues to have intermittent supply gaps. The FDA drug shortage database lists Cefprozil oral suspension with estimated resupply dates that have been periodically revised.

Prescribing Implications

The shortage creates several clinical decision points:

Empiric Therapy Selection

For conditions where Cefprozil is one of several appropriate first-line agents (acute sinusitis, otitis media, bronchitis exacerbation), consider checking local availability before prescribing. Selecting an antibiotic that your patient can actually obtain is clinically more valuable than defaulting to a preferred agent that sits unfilled at the pharmacy.

Therapeutic Substitution

When Cefprozil is unavailable, the following alternatives offer comparable spectrum and clinical efficacy for most approved indications:

• Cefuroxime (Ceftin): Closest match. Second-generation cephalosporin with nearly identical spectrum. Adult dose: 250–500 mg BID. Available as tablets and suspension. Note: should be taken with food for optimal absorption.
• Amoxicillin/Clavulanate (Augmentin): Broader spectrum with beta-lactamase inhibitor coverage. Higher incidence of GI side effects. Preferred for otitis media with treatment failure or resistant organisms.
• Cephalexin (Keflex): First-generation cephalosporin. Adequate for pharyngitis and uncomplicated skin infections. More limited gram-negative coverage — less ideal for sinusitis or otitis media caused by H. influenzae.
• Azithromycin (Zithromax): Reserve for penicillin/cephalosporin-allergic patients. Increasing macrolide resistance in S. pneumoniae limits utility for respiratory infections in some regions.

Pediatric Considerations

The oral suspension shortage disproportionately affects pediatric patients. If the Cefprozil suspension is unavailable:

• Check if Cefuroxime or Amoxicillin/Clavulanate suspension is available
• For older children who can swallow tablets, Cefprozil 250 mg tablets may be an option (scored for splitting)
• Compounding pharmacies can sometimes prepare oral suspensions from tablet stock — confirm with the pharmacy

Current Availability Picture

Based on pharmacy supply data and FDA reporting:

• Cefprozil 250 mg tablets: Generally available; occasional regional gaps
• Cefprozil 500 mg tablets: Generally available; better supply than 250 mg in some markets
• Cefprozil 125 mg/5 mL suspension: Intermittently unavailable; check before prescribing
• Cefprozil 250 mg/5 mL suspension: Intermittently unavailable; check before prescribing

Availability varies significantly by region and distributor. Chain pharmacies and independent pharmacies source from different wholesalers, so stock can differ even within the same zip code.

Cost and Access Considerations

Cefprozil is available only as a generic. Typical costs:

• Insured patients: $5–$15 copay (Tier 1 or Tier 2 on most formularies)
• Uninsured patients, cash price: $30–$60 for a standard 10-day course
• With discount card (GoodRx, SingleCare): $15–$35

No prior authorization or step therapy is typically required. The brand name Cefzil is discontinued with no active manufacturer savings program.

For uninsured or underinsured patients, discount card programs and patient assistance through NeedyMeds or RxAssist may help. Our patient-facing cost guide covers this in detail: How to save money on Cefprozil.

Tools and Resources for Providers

Medfinder for Providers offers real-time pharmacy inventory data, allowing you or your staff to verify Cefprozil availability before sending the prescription. This reduces patient callbacks, pharmacy rejections, and treatment delays.

Additional resources:

• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — official shortage status and manufacturer updates
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — clinical guidance and alternative recommendations
• Medfinder Provider Tools: medfinder.com/providers — real-time stock verification

Looking Ahead

Generic antibiotic supply remains structurally fragile. The combination of concentrated manufacturing (few producers), low margins, and demand volatility means that Cefprozil — and similar generic antibiotics — will likely continue to experience periodic disruptions.

Proactive steps that can help your practice navigate these shortages:

1. Check availability before prescribing using Medfinder or by confirming with the patient's pharmacy
2. Maintain familiarity with 2–3 therapeutic alternatives for each commonly prescribed antibiotic
3. Educate patients about pharmacy options — independent pharmacies and mail-order services may have better access
4. Consider building shortage protocols into your EHR workflow (e.g., shortage alerts, preferred alternative defaults)

Final Thoughts

The Cefprozil shortage in 2026 is a manageable but ongoing clinical challenge. Staying informed about availability, maintaining a flexible prescribing approach, and leveraging real-time tools like Medfinder for Providers will help ensure your patients get the antibiotics they need without unnecessary delays.

For a step-by-step guide on helping patients locate Cefprozil, see our companion article: How to help your patients find Cefprozil in stock.